Company intelligence / Profile preview

Transfynydd

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Transfynydd is a biotechnology company focused on the discovery and development of novel antiviral therapies. The company's primary focus is on developing small molecule inhibitors targeting viral proteases to treat infections such as COVID-19. Transfynydd was founded by a team of experienced biotech entrepreneurs and scientists with the goal of creating highly potent and selective oral treatments for viral diseases. The company operates as part of the portfolio of companies launched by the life sciences venture firm, Foresite Labs.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Transfynydd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transfynydd.

Explore the full profile